Overview
Target discovery is a critical step in drug development, particularly in genomic research where identifying precise molecular interactions can significantly accelerate therapeutic innovation. siRNA-based screening provides valuable insights into gene function and pathway regulation, but extracting actionable knowledge from large experimental datasets requires advanced data analysis and computational methods.
Excelra partnered with a leading biotech company to reanalyze their existing siRNA screening database and uncover potential therapeutic targets. By leveraging advanced Bioinformatics Solutions and Computational Biology Services, Excelra implemented a comprehensive analytical framework to identify on-target and off-target interactions while integrating pathway and toxicity insights for informed therapeutic target discovery.
Our client
The client is a biotech company based in the European Union engaged in genomic research and drug discovery initiatives. Their objective was to revisit and reanalyze an existing database of siRNA experiments to uncover previously unidentified therapeutic targets and gain deeper insights into molecular pathways.
Client’s challenge
The client possessed a large siRNA screening dataset but needed advanced analytical capabilities to extract meaningful insights.
Key challenges included:
- Identifying accurate siRNA on-target and off-target interactions
- Understanding pathway-level effects of gene silencing
- Integrating experimental data with toxicity screening results
- Establishing reliable thresholds for evaluating gene targets
- Translating complex genomic data into actionable drug discovery insights
Addressing these challenges required specialized expertise in genomics data analysis and pathway modeling.
Client’s goals
The client’s primary objectives were:
- Identification and selection of siRNA on/off-targets
- Conducting in-depth pathway and network analysis
- Integrating analytical findings with toxicity screening data
- Improving understanding of molecular pathways influencing therapeutic outcomes
Achieving these objectives would help the client refine their target discovery pipeline and support future therapeutic development.
Our Approach
Excelra implemented a comprehensive bioinformatics workflow designed to analyze siRNA screening data and identify meaningful target interactions.
siRNA hit calling and target identification
Excelra performed precise siRNA hit calling to determine the effectiveness of gene silencing and identify both on-target and off-target interactions.
Selection of siRNA candidates
A curated set of siRNA candidates was selected for subsequent toxicity screening based on their biological relevance and potential therapeutic value.
Threshold definition and toxicity screening
Excelra established critical thresholds to ensure reliable analysis:
- Cell viability thresholds
- Toxicity indicators
- Household gene stability metrics
These thresholds enabled robust screening of candidate targets and ensured biological reliability.
Pathway and network analysis
To understand the broader biological implications of siRNA interactions, Excelra conducted in-depth pathway and network analysis.
This approach enabled identification of gene interactions within biological pathways and helped uncover potential therapeutic targets for further investigation.
The analytical framework also aligns with modern data-driven drug discovery methodologies, similar to approaches discussed in drug discovery using big data and artificial intelligence.
Results
Excelra successfully supported the client in extracting valuable insights from their siRNA dataset.
Key outcomes
- Identification of siRNA on-target and off-target interactions
- Improved understanding of molecular pathways affected by gene silencing
- Integration of siRNA screening data with toxicity analysis
- Identification of potential therapeutic targets for further research
Key benefits
- Improved target identification
The analysis enabled accurate identification of siRNA interactions and potential therapeutic targets. - Enhanced pathway insights
Network and pathway analysis revealed deeper insights into gene regulatory mechanisms. - Data-Driven drug discovery
The integrated framework supported better decision-making in genomic research and therapeutic development.
Conclusion
By reanalyzing the client’s siRNA screening database, Excelra provided deeper insights into gene interactions and molecular pathways. Through advanced bioinformatics workflows and pathway analysis, the project enabled identification of potential therapeutic targets while integrating toxicity screening insights.
This case study highlights Excelra’s expertise in bioinformatics, computational biology, and data-driven genomic research, helping life sciences organizations accelerate target discovery and therapeutic development.
For similar success stories, explore related case studies such as:
